Maze Therapeutics, Inc. (MAZE)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

27.11 on 9 Oct 2026

0 buys10 sales at will45 planned sales

Fiscal year 2024, ended 31 Dec 2024, as filed

Revenue

$167.50M

Net income

$52.23M

Free cash flow

$74.81M

Operating margin

34.4%

Net margin

31.2%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
1 Oct 2026	Coloma Jason V Chief Executive Officer	Sold on a plan	$862.19K	14.3%
1 Oct 2026	Bernstein Harold President, R&D & CMO	Sold on a plan	$434.74K	100%
1 Oct 2026	Coloma Jason V Chief Executive Officer	Sold on a plan	$70.07K	14.3%
29 Sep 2026	Dandekar Atul CSBO	Sold on a plan	$202.92K	18.8%
4 Sep 2026	Bernstein Harold President, R&D & CMO	Sold on a plan	$254.50K	100%
3 Sep 2026	Coloma Jason V Chief Executive Officer	Sold at will	$296.81K	29.4%

57out of 100

Profitability 100

Financial strength 50

Growth n/a

Insiders 0

Strongest on profitability (100), weakest on insiders (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$23.67M

55 sales

Planned sales

82%

under a 10b5-1 plan